This first-in-human trial evaluates safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-514 as monotherapy and in combination with budigalimab (BDG), a PD-1–blocking …

2024年10月24日 · ABBV-514 is an anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head …

ABBV-514 is an afucosylated monoclonal antibody that binds CCR8 and is designed to enhance antibody-dependent cellular cytotoxicity to deplete tumor-in ltrating Tregs.This rst-in-human …

In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and …

Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called …

This first-in-human study evaluates the safety, pharmacology, and preliminary eficacy of ABBV-514 as monotherapy and in combination with budigalimab, a programmed cell death protein 1 …

Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called …

CCR8-targeted Treg depletion and PD-1 blockade combine to divert CD8+ T cells from exhaustion associated transcriptional trajectories within the tumor microenvironment (SITC …

2021年8月12日 · Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in …

この試験は、標準治療後の進行性固形がんを対象にした第I相の臨床試験で、抗CCR-8抗体の単剤または抗PD-1抗体との併用療法を投与する臨床試験です。 注：上記の患者選択基準は概要 …